MX383715B - Formas sólidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y usos de las mismas. - Google Patents

Formas sólidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y usos de las mismas.

Info

Publication number
MX383715B
MX383715B MX2016006271A MX2016006271A MX383715B MX 383715 B MX383715 B MX 383715B MX 2016006271 A MX2016006271 A MX 2016006271A MX 2016006271 A MX2016006271 A MX 2016006271A MX 383715 B MX383715 B MX 383715B
Authority
MX
Mexico
Prior art keywords
solid forms
hydroxypyridine
chlorophenyl
carbonyl
amino
Prior art date
Application number
MX2016006271A
Other languages
English (en)
Other versions
MX2016006271A (es
Inventor
Ann W Newman
Anne Luong
James Densmore Copp
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Publication of MX2016006271A publication Critical patent/MX2016006271A/es
Publication of MX383715B publication Critical patent/MX383715B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/803—Processes of preparation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan en la presente formas sólidas que comprenden ácido { [5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones que comprenden las formas sólidas, métodos para elaborar las formas sólidas y métodos de su uso para el tratamiento de diversa enfermedades y/o trastornos.
MX2016006271A 2013-11-15 2014-11-14 Formas sólidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y usos de las mismas. MX383715B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361904803P 2013-11-15 2013-11-15
PCT/US2014/065631 WO2015073779A1 (en) 2013-11-15 2014-11-14 Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Publications (2)

Publication Number Publication Date
MX2016006271A MX2016006271A (es) 2017-05-04
MX383715B true MX383715B (es) 2025-03-14

Family

ID=53058045

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2021001169A MX2021001169A (es) 2013-11-15 2014-11-14 Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.
MX2016006271A MX383715B (es) 2013-11-15 2014-11-14 Formas sólidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y usos de las mismas.
MX2021007268A MX2021007268A (es) 2013-11-15 2016-05-13 Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2021001169A MX2021001169A (es) 2013-11-15 2014-11-14 Formas sólidas de ácido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acético, composiciones, y usos de las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021007268A MX2021007268A (es) 2013-11-15 2016-05-13 Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.

Country Status (24)

Country Link
US (7) US9701636B2 (es)
EP (2) EP3068394A4 (es)
JP (5) JP2016537365A (es)
KR (2) KR102495018B1 (es)
CN (2) CN114890943A (es)
AR (2) AR099354A1 (es)
AU (4) AU2014348523B2 (es)
BR (1) BR112016011065B1 (es)
CA (1) CA2930128A1 (es)
CL (1) CL2016001150A1 (es)
CR (2) CR20200220A (es)
DO (1) DOP2016000109A (es)
IL (2) IL245634A0 (es)
MA (1) MA39033A1 (es)
MX (3) MX2021001169A (es)
MY (1) MY180626A (es)
PE (1) PE20160945A1 (es)
PH (2) PH12021551124A1 (es)
RU (2) RU2021125455A (es)
SA (1) SA516371129B1 (es)
SG (2) SG10202012791TA (es)
TW (5) TWI902264B (es)
WO (1) WO2015073779A1 (es)
ZA (3) ZA201603189B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009000286A (es) * 2006-06-26 2009-03-20 Procter & Gamble Inhibidores de prolil hidroxilasa y metodos de uso.
NO2686520T3 (es) 2011-06-06 2018-03-17
CN114404414A (zh) 2013-06-13 2022-04-29 阿克比治疗有限公司 用于治疗贫血症的组合物和方法
KR102495018B1 (ko) 2013-11-15 2023-02-06 아케비아 테라퓨틱스 인코포레이티드 ｛[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노｝아세트산의 고체형, 이의 조성물 및 용도
WO2015112831A1 (en) * 2014-01-23 2015-07-30 Akebia Therapeutics, Inc. Compositions and methods for treating ocular diseases
EP3247355A4 (en) 2015-01-23 2018-06-13 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
EA036920B1 (ru) 2015-04-01 2021-01-15 Экебиа Терапьютикс, Инк. Композиции и способы для лечения анемии
CN105837502A (zh) * 2016-04-05 2016-08-10 湖南欧亚生物有限公司 一种Vadadustat的合成方法
WO2018108101A1 (zh) 2016-12-13 2018-06-21 苏州科睿思制药有限公司 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法
WO2019028150A1 (en) * 2017-08-01 2019-02-07 Akebia Therapeutics, Inc. COMPOSITIONS FOR USE IN METHODS OF TREATING HEMOGLOBINOPATHIES
TW202406895A (zh) 2018-05-09 2024-02-16 美商阿克比治療有限公司 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法
WO2020075199A1 (en) 2018-10-12 2020-04-16 Mylan Laboratories Limited Polymorphic forms of vadadustat
US11970450B2 (en) 2018-11-28 2024-04-30 Sandoz Ag Multi-component crystals of an orally available HIF prolyl hydroxylase inhibitor
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
IT202000014116A1 (it) * 2020-06-12 2021-12-12 Olon Spa Nuovo composto cristallino di vadadustat
CN111825606A (zh) * 2020-06-17 2020-10-27 上海希迈医药科技有限公司 一种伐度司他晶型及其制备方法
WO2021257800A1 (en) * 2020-06-19 2021-12-23 Akebia Therapeutics, Inc. Modulation of drug-drug interactions of vadadustat
GB202011431D0 (en) * 2020-07-23 2020-09-09 Johnson Matthey Plc Polymorphs of vadadustat and methods for preparing the polymorphs
CN114105866A (zh) * 2020-08-26 2022-03-01 广东东阳光药业有限公司 一种低氧诱导因子脯氨酰羟化酶抑制剂的晶型及其制备方法
CN114105867A (zh) * 2020-09-01 2022-03-01 广东东阳光药业有限公司 一种低氧诱导因子脯氨酰羟化酶抑制剂的晶型及其制备方法
CN115996720A (zh) * 2020-09-04 2023-04-21 广东东阳光药业有限公司 一种低氧诱导因子脯氨酰羟化酶抑制剂的晶型及其制备方法
AU2022206302A1 (en) 2021-01-08 2023-08-17 Akebia Therapeutics, Inc. Therapeutic methods using vadadustat
WO2022179967A1 (en) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat for treating covid-19 in a hospitalized subject
WO2022187142A1 (en) * 2021-03-01 2022-09-09 Akebia Therapeutics, Inc. Modulation of drug-drug interactions of vadadustat

Family Cites Families (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3894920A (en) 1971-12-21 1975-07-15 Sagami Chem Res Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
US4016287A (en) 1972-07-17 1977-04-05 Boehringer Ingelheim Gmbh Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
US5067954A (en) 1988-07-25 1991-11-26 Ilizarov Gavriil A Distraction apparatus for plastic reconstruction of hand
TW219933B (es) 1990-02-26 1994-02-01 Lilly Co Eli
US5405613A (en) 1991-12-11 1995-04-11 Creative Nutrition Canada Corp. Vitamin/mineral composition
TW352384B (en) 1992-03-24 1999-02-11 Hoechst Ag Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP0650960B1 (de) 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
ES2101421T3 (es) 1993-11-02 1997-07-01 Hoechst Ag Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
TW406076B (en) 1993-12-30 2000-09-21 Hoechst Ag Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
DE4410423A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410480A1 (de) 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
IL135495A (en) 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
JPH09221476A (ja) 1995-12-15 1997-08-26 Otsuka Pharmaceut Co Ltd 医薬組成物
CA2253282A1 (en) 1996-04-30 1997-11-06 Hoechst Aktiengesellschaft 3-alkoxypyridine-2-carboxylic acid amide esters, their preparation and their use as drugs
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19650215A1 (de) 1996-12-04 1998-06-10 Hoechst Ag 3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
US6420427B1 (en) 1997-10-09 2002-07-16 Ono Pharmaceutical Co., Ltd. Aminobutyric acid derivatives
DE19746287A1 (de) 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
ES2224620T3 (es) 1998-03-23 2005-03-01 Aventis Pharmaceuticals Inc. Derivados de piperidinilo y n-aminopiperidinilo.
PT1107974E (pt) 1998-08-27 2006-10-31 Teva Pharma Novas formas de hidratos de alendronato de sodio, processos para a sua producao e suas composicoes farmaceuticas
WO2000032551A1 (en) 1998-11-27 2000-06-08 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
US6159379A (en) 1999-05-04 2000-12-12 Baker Hughes Incorporated Organic ammonium salts for the removal of water soluble organics in produced water
JP2001048786A (ja) 1999-08-05 2001-02-20 Yamanouchi Pharmaceut Co Ltd 三環式ヘテロアリール誘導体
WO2001010441A1 (en) 1999-08-11 2001-02-15 Teva Pharmaceutical Industries Ltd. Torsemide polymorphs
DE60018100T2 (de) 1999-11-17 2005-09-15 Teva Pharmaceutical Industries Ltd. Polymorphe form von atorvastatin-calcium
CA2394200C (en) 1999-12-14 2006-10-03 Biogal Gyogyszergyar Rt. Novel forms of pravastatin sodium
HRP20050176A2 (en) 1999-12-16 2005-08-31 Teva Pharmaceutical Industries Ltd. Novel processes for making - and a new crystalline form of-leflunomide
WO2001044262A1 (en) 1999-12-16 2001-06-21 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs and novel polymorph iv
PT1248605E (pt) 1999-12-21 2007-03-30 Teva Pharma Novos polimorfos de cloridrato de sertralina, processos para a sua preparação, composições que os contêm e métodos para a sua utilização
NZ519984A (en) 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
AU2001222619C1 (en) 2000-01-11 2006-01-12 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
US6589758B1 (en) 2000-05-19 2003-07-08 Amgen Inc. Crystal of a kinase-ligand complex and methods of use
KR101098749B1 (ko) 2000-07-27 2011-12-23 테바 파마슈티컬 인더스트리즈 리미티드 결정질의 순수한 모다피닐 및 이의 제조 방법
KR20030059206A (ko) 2000-10-19 2003-07-07 테바 파마슈티컬 인더스트리즈 리미티드 결정질 벤라팍신 염기 및 벤라팍신 히드로클로라이드의신규한 다형태, 이의 제조 방법
US20020183553A1 (en) 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US20020107275A1 (en) 2000-10-30 2002-08-08 Ramy Lidor-Hadas Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
IL155734A0 (en) 2000-11-03 2003-11-23 Teve Pharmaceutical Ind Ltd Atorvastatin hemi-calcium form vii
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
HUP0303154A3 (en) 2001-02-12 2009-08-28 Teva Pharma New crystal forms of oxcarbazepine and processes for their preparation
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US20040146964A1 (en) 2001-03-21 2004-07-29 Maxwell Patrick Henry Assays, methods and means
EP1392303A4 (en) 2001-04-09 2005-01-26 Teva Pharma FEXOFENADINE HYDROCHLORIDE POLYMORPHS
SE0101327D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab New crystalline forms
CA2453751A1 (en) 2001-08-01 2003-02-13 Biogal Gyogyszergyar Rt. Purification and crystalline forms of zapelon
EP1436295A4 (en) 2001-09-07 2007-07-11 Teva Pharma CRISTALLINE FORMS OF VALACYCLOVIR HYDROCHLORIDE
ES2272781T5 (es) 2001-10-03 2010-04-06 Teva Pharmaceutical Industries Ltd. Preparacion de levofloxacino hemihidratado.
US6566088B1 (en) 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
EP1453509A2 (en) 2001-11-08 2004-09-08 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine base
MXPA04004657A (es) 2001-11-14 2004-08-13 Teva Pharma Formas amorfas y cristalinas de potasio de losartan y proceso para su preparacion.
WO2003047531A2 (en) 2001-12-04 2003-06-12 Biogal Gyogyszergyar Rt Preparation of orlistat and orlistat crystalline forms
CN102526044A (zh) 2001-12-06 2012-07-04 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
CA2470479A1 (en) 2001-12-18 2003-06-26 Teva Pharmaceutical Industries Ltd. Polymorphs of clopidogrel hydrogensulfate
CN1625394A (zh) 2001-12-28 2005-06-08 拜奥盖尔药厂有限公司 结晶和无定形莫匹罗星钙的制备方法
PL371409A1 (en) 2002-01-15 2005-06-13 Teva Pharmaceutical Industries Ltd. Crystalline solids of carvedilol and processes for their preparation
AU2003217653A1 (en) 2002-02-15 2003-09-09 Teva Pharmaceutical Industries Ltd. Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix
JP4414237B2 (ja) 2002-03-20 2010-02-10 テバ ファーマシューティカル インダストリーズ リミティド ケチアピンヘミフマレートの結晶形
CA2480352A1 (en) 2002-03-27 2003-10-09 Teva Pharmaceutical Industries Ltd. Lansoprazole polymorphs and processes for preparation thereof
CN1658842A (zh) 2002-04-11 2005-08-24 特瓦制药工业有限公司 利塞膦酸钠的新多晶型物和假多晶型物
WO2003093217A1 (en) 2002-04-29 2003-11-13 Teva Pharmaceutical Industries Ltd. Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
KR20040104677A (ko) 2002-04-30 2004-12-10 비오갈 기오기스제르갸르 알티. 신규의 온단세트론 결정 형태, 그 제조 방법, 그 신규의결정 형태를 함유하는 약학 조성물 및 이들을 이용한구역질 치료 방법
CA2485262A1 (en) 2002-05-10 2003-11-20 Teva Pharmaceutical Industries Ltd Novel crystalline forms of gatifloxacin
AU2003248657A1 (en) 2002-06-10 2003-12-22 Teva Pharmaceutical Industries Ltd. Polymorphic form xvi of fexofenadine hydrochloride
JP2005532364A (ja) 2002-06-14 2005-10-27 テバ ファーマシューティカル インダストリーズ リミティド ガチフロキサシンの新規結晶質形態
WO2004009532A1 (en) 2002-07-18 2004-01-29 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
US20040022764A1 (en) * 2002-07-31 2004-02-05 Hanan Polansky Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease
PL374993A1 (en) 2002-08-06 2005-11-14 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of gatifloxacin
AU2003268213A1 (en) 2002-08-26 2004-03-11 Teva Pharmaceutical Industries Ltd. Crystalline solid famciclovir forms i, ii, iii and preparation thereof
US20050043329A1 (en) 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
EP1572643A2 (en) 2002-11-28 2005-09-14 Teva Pharmaceutical Industries Ltd. Crystalline form f of atorvastatin hemi-calcium salt
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
EP1485097A1 (en) 2002-12-12 2004-12-15 Teva Pharmaceutical Industries Limited Crystalline forms of gatifloxacin and processes for preparation
WO2004058773A1 (en) 2002-12-24 2004-07-15 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
WO2004080461A2 (en) 2003-03-12 2004-09-23 TEVA Gyógyszergyár Részvénytársaság Stable pharmaceutical compositions of desloratadine
EP1601667A2 (en) 2003-03-12 2005-12-07 Teva Pharmaceutical Industries Limited Crystalline and amorphous solids of pantoprazole and processes for their preparation
WO2004083192A1 (en) 2003-03-17 2004-09-30 Teva Pharmaceutical Industries Ltd. Polymorphis of valsartan
WO2004103999A1 (en) 2003-05-15 2004-12-02 TEVA Gyógyszergyár Részvénytársaság AZTREONAM β POLYMORPH WITH VERY LOW RESIDUAL SOLVENT CONTENT
KR100871621B1 (ko) 2003-06-02 2008-12-02 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로비르 히드로클로라이드의 신규한 결정질 형태
EP1546146A1 (en) 2003-06-03 2005-06-29 Teva Pharmaceutical Industries Limited POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION
EP2357175A1 (en) 2003-06-06 2011-08-17 Fibrogen, Inc. isoquinoline derivatives AND THEIR USE IN INCREASING ENDOGENEOUS ERYTHROPOIETIN
JP2007524619A (ja) 2003-06-18 2007-08-30 テバ ファーマシューティカル インダストリーズ リミティド フルバスタチンナトリウム結晶型、その調製方法、これを含有する組成物、およびその使用法
US7368468B2 (en) 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
GB0314129D0 (en) 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
ATE425170T1 (de) 2003-07-03 2009-03-15 Teva Pharma Kristallformen der zoledronsäure und deren natrioumsalze, amorphes natriumzoledronat und verfahren zu deren herstellung
TW200526596A (en) 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
US20050165085A1 (en) 2003-12-16 2005-07-28 Marioara Mendelovici Polymorphic forms of tegaserod base and salts thereof
US7504504B2 (en) 2003-12-16 2009-03-17 Teva Pharmaceutical Industries Ltd. Methods of preparing aripiprazole crystalline forms
US20050197347A1 (en) 2003-12-18 2005-09-08 Judith Aronhime Polymorphic form B2 of ziprasidone base
US20050187244A1 (en) 2004-01-30 2005-08-25 Entire Interest. Montelukast sodium polymorphs
EP1708708A1 (en) 2004-01-30 2006-10-11 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
US7692023B2 (en) 2004-02-11 2010-04-06 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
WO2005108370A1 (ja) 2004-04-16 2005-11-17 Ajinomoto Co., Inc. ベンゼン化合物
EP1628959A2 (en) 2004-04-26 2006-03-01 Teva Pharmaceutical Industries Ltd Crystalline forms of fexofenadine hydrochloride and processes for their preparation
MXPA06012793A (es) 2004-05-07 2007-07-18 Teva Pharma Formas polimorficas de nateglinida.
EP1747223A1 (en) 2004-05-18 2007-01-31 Teva Pharmaceutical Industries Ltd. Drying process for preparing crystalline solid famciclovir
WO2005113482A1 (en) 2004-05-20 2005-12-01 Teva Pharmaceutical Fine Chemicals S.R.L. Levalbuterol hydrochloride polymorph b
WO2006002348A2 (en) 2004-06-23 2006-01-05 Teva Pharmaceutical Industies Ltd. Solid and crystalline ibandronic acid
JP2007504173A (ja) 2004-06-29 2007-03-01 テバ ファーマシューティカル インダストリーズ リミティド リネゾリドのｉｖ型結晶
TWI299333B (en) 2004-07-01 2008-08-01 Teva Pharma Crystalline forms of 1,24(s)-dihydroxy vitamin d2
JP2008506784A (ja) 2004-07-20 2008-03-06 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ 結晶形ミコフェノール酸・ナトリウム
WO2006020348A2 (en) 2004-07-22 2006-02-23 Teva Pharmaceutical Fine Chemicals S.R.L. Polymorphs of atomoxetine hydrochloride
EP1711464A2 (en) 2004-07-22 2006-10-18 Teva Pharmaceutical Industries Ltd Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
DE202005021414U1 (de) 2004-08-23 2008-03-20 Teva Pharmaceutical Industries Ltd. Festes und kristallines Ibandronat-Natrium
EP1704152A2 (en) 2004-09-21 2006-09-27 Teva Pharmaceutical Industries Ltd Crystalline clopidogrel hydrobromide and processes for preparation thereof
US20060148851A1 (en) 2004-09-28 2006-07-06 Shlomit Wizel Fexofenadine crystal form and processes for its preparation thereof
CA2582092A1 (en) 2004-11-02 2006-05-11 Teva Pharmaceutical Industries Ltd. Tadalafil crystal forms and processes for preparing them
WO2006050509A2 (en) 2004-11-03 2006-05-11 Teva Pharmaceutical Industries Ltd. Amorphous and polymorphic forms of telmisartan sodium
EP1812428A2 (en) 2004-11-19 2007-08-01 Teva Pharmaceutical Industries Ltd Zolmitriptan crystal forms
WO2006060616A1 (en) 2004-12-01 2006-06-08 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Processes for producing crystalline macrolides
WO2006060808A1 (en) 2004-12-03 2006-06-08 Teva Pharmaceutical Industries Ltd. Ezetimibe polymorphs
HRP20090676T1 (hr) 2005-01-11 2010-01-31 Teva Pharmaceutical Fine Chemicals S.R.L. Postupak dobivanja 1-amino-3,5-dimetiladamantan-hidroklorida
US20060270859A1 (en) 2005-01-27 2006-11-30 Santiago Ini Duloxetine HCl polymorphs
WO2006084210A2 (en) 2005-02-04 2006-08-10 Regents Of The University Of California, San Diego Hif modulating compounds and methods of use thereof
CN101128420A (zh) 2005-02-24 2008-02-20 泰华制药工业有限公司 拉多斯迪戈酒石酸盐结晶体、其制备方法及其药物组合物
EP1866295A2 (en) 2005-02-24 2007-12-19 Teva Pharmaceutical Industries Ltd Processes for the preparation of linezolid intermediate
WO2006096809A1 (en) 2005-03-08 2006-09-14 Teva Pharmaceutical Industries Ltd. Crystal forms of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine oxalate and the preparation thereof
WO2006098834A2 (en) 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
EP1866275A1 (en) 2005-04-06 2007-12-19 Teva Pharmaceutical Industries Ltd. Crystalline forms of pregabalin
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
NZ563692A (en) 2005-05-23 2011-04-29 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
CA2604760C (en) 2005-05-23 2012-06-26 Cadbury Adams Usa Llc Taste potentiator compositions and beverages containing same
ATE445587T1 (de) 2005-05-23 2009-10-15 Teva Pharma Verfahren zur herstellung von cinacalcet hydrochlorid kristallform i
AU2006254897A1 (en) 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a HIF-alpha stabilising agent
WO2006135757A1 (en) 2005-06-09 2006-12-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of carvedilol and processes for their preparation
US20070100165A1 (en) 2005-06-09 2007-05-03 Ronen Borochovitz Process for preparation of sertraline hydrochloride form I
MX2007016160A (es) 2005-06-15 2008-03-07 Fibrogen Inc Uso de moduladoers de hif-1 alfa para el tratamiento contra el cancer.
WO2007002314A2 (en) 2005-06-22 2007-01-04 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod maleate
WO2007033216A2 (en) 2005-09-12 2007-03-22 Beth Israel Deaconess Medical Center Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
WO2007038571A2 (en) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007038676A2 (en) 2005-09-28 2007-04-05 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ladostigil tartrate
WO2007047194A2 (en) 2005-10-11 2007-04-26 Dana-Farber Cancer Institute, Inc. Methods for treating mitf-related disorders
DK1937642T3 (en) 2005-10-19 2014-12-15 Teva Pharma Crystals of sodium laquinimod and the process for its preparation
KR20070088764A (ko) 2005-10-31 2007-08-29 테바 파마슈티컬 인더스트리즈 리미티드 세프디니어 칼륨염의 결정형
EP1828208A2 (en) 2005-10-31 2007-09-05 Teva Pharmaceutical Industries Ltd Crystalline form of cefdinir cesium salt
WO2007059307A2 (en) 2005-11-15 2007-05-24 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of telithromycin
EP1828098A1 (en) 2005-11-22 2007-09-05 Teva Pharmaceutical Industries Ltd Crystal forms of cinacalcet hci and processes for their preparation
US7728130B2 (en) 2005-12-09 2010-06-01 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity
CA2633268A1 (en) 2005-12-13 2007-06-21 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof
US7851476B2 (en) 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
EP1874767A2 (en) 2006-01-05 2008-01-09 Teva Gyogyszergyár Zártköruen Muködo Részvenytarsaság Production of dolasetron
CA2635370A1 (en) 2006-01-09 2007-07-09 Btg International Limited Modulators of hypoxia inducible factor-1 and related uses
EP1983823A1 (en) 2006-01-17 2008-10-29 VIB vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
WO2007084761A1 (en) 2006-01-18 2007-07-26 Teva Pharmaceutical Industries Ltd. Maleate salt of tegaserod and crystalline forms thereof
US20070208053A1 (en) 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
JP4801451B2 (ja) 2006-01-19 2011-10-26 株式会社日立ハイテクノロジーズ 走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
ITMI20060179A1 (it) 2006-02-02 2007-08-03 Abiogen Pharma Spa Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
MX2007012605A (es) 2006-02-21 2008-01-11 Teva Pharma Formas cristalinas novedosas de armodafinil y preparacion de ellas.
DE07752084T1 (de) 2006-02-27 2008-06-05 Teva Pharmaceutical Industries Ltd. Neuartige formen von fluvastatin-natrium und herstellung davon
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
TW200808793A (en) 2006-03-07 2008-02-16 Smithkline Beecham Corp Prolyl hydroxylase inhibitors
US20080027223A1 (en) 2006-03-23 2008-01-31 Teva Pharmaceutical Industries Ltd. Polymorphs of eszopiclone malate
WO2007136990A2 (en) 2006-05-16 2007-11-29 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
US20070293575A1 (en) 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
AR061570A1 (es) 2006-06-23 2008-09-03 Smithkline Beecham Corp Compuesto de glicina sustituido en el n heteroaromatico composicion farmaceutica que lo comprende, su uso para preparar un medicamento, procedimientos para preparar dicha composicion farmaceutica y para preparar el compuesto
MX2009000286A (es) 2006-06-26 2009-03-20 Procter & Gamble Inhibidores de prolil hidroxilasa y metodos de uso.
TW200845991A (en) 2007-01-12 2008-12-01 Smithkline Beecham Corp N-substituted glycine derivatives: hydroxylase inhibitors
CL2008000065A1 (es) 2007-01-12 2008-09-22 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia.
CA2683758A1 (en) 2007-04-18 2008-10-30 Merck & Co., Inc. Novel 1,8-naphthyridine compounds
AU2008241577B2 (en) 2007-04-18 2011-04-07 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
AU2008248234B2 (en) 2007-05-04 2011-02-03 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
CA2685942A1 (en) 2007-05-16 2008-11-27 Merck & Co., Inc. Spiroindalones
TW200908984A (en) 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
EP2188295A4 (en) 2007-08-10 2011-11-16 Crystalgenomics Inc PYRIDINE DERIVATIVES AND METHODS OF USE
WO2009039323A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009039321A1 (en) 2007-09-19 2009-03-26 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009043093A1 (en) 2007-10-04 2009-04-09 Newsouth Innovations Pty Limited Hif inhibition
WO2009049112A1 (en) 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
BRPI0820343A2 (pt) 2007-11-08 2017-08-22 Genentech Inc Anticorpos de antifator b e seus usos
WO2009067790A1 (en) 2007-11-26 2009-06-04 Uti Limited Partnership STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
AU2008329746A1 (en) 2007-11-30 2009-06-04 Glaxosmithkline Llc Prolyl hydroxylase inhibitors
JP2011508725A (ja) 2007-11-30 2011-03-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
EP2227475B1 (en) 2007-12-03 2014-02-19 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
US20100298324A1 (en) 2007-12-19 2010-11-25 Smith Kline Beecham Corporation Prolyl Hydroxylase Inhibitors
US20110003013A1 (en) 2008-01-04 2011-01-06 Garvan Institute Of Medical Research Method of increasing metabolism
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
AR071997A1 (es) * 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
NO2686520T3 (es) * 2011-06-06 2018-03-17
MX2013014310A (es) 2011-06-06 2014-01-23 Akebia Therapeutics Inc Compuestos y composiciones para estabilizar el factor-2 alfa inducible por hipoxia como un metodo para tratar el cancer.
CN104024227B8 (zh) 2011-07-22 2025-07-29 北京贝美拓新药研发有限公司 抑制脯氨酸羟化酶活性的化合物的晶型及其应用
US8772895B2 (en) 2011-11-28 2014-07-08 Taiwan Semiconductor Manufacturing Company, Ltd. Dark current reduction for back side illuminated image sensor
EP2637274B1 (en) 2012-03-05 2022-05-04 Vetco Gray Scandinavia AS Power cable termination arrangement
CN114404414A (zh) 2013-06-13 2022-04-29 阿克比治疗有限公司 用于治疗贫血症的组合物和方法
KR102495018B1 (ko) 2013-11-15 2023-02-06 아케비아 테라퓨틱스 인코포레이티드 ｛[5-(3-클로로페닐)-3-하이드록시피리딘-2-카보닐]아미노｝아세트산의 고체형, 이의 조성물 및 용도
WO2015112831A1 (en) 2014-01-23 2015-07-30 Akebia Therapeutics, Inc. Compositions and methods for treating ocular diseases
EP3247355A4 (en) 2015-01-23 2018-06-13 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
CA2979985A1 (en) 2015-03-20 2016-09-29 Akebia Therapeutics, Inc. Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
EA036920B1 (ru) 2015-04-01 2021-01-15 Экебиа Терапьютикс, Инк. Композиции и способы для лечения анемии
WO2018108101A1 (zh) 2016-12-13 2018-06-21 苏州科睿思制药有限公司 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸的新晶型及其制备方法
TW202406895A (zh) 2018-05-09 2024-02-16 美商阿克比治療有限公司 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法
KR20220133176A (ko) 2019-10-31 2022-10-04 아케비아 테라퓨틱스 인코포레이티드 바다두스타트를 사용하는 치료 방법
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Also Published As

Publication number Publication date
CR20160222U (es) 2016-08-26
US20240122910A1 (en) 2024-04-18
CN105916502A (zh) 2016-08-31
MY180626A (en) 2020-12-03
JP2019167353A (ja) 2019-10-03
TW201605801A (zh) 2016-02-16
CN114890943A (zh) 2022-08-12
US9987262B2 (en) 2018-06-05
AU2014348523A1 (en) 2016-06-09
US20200345711A1 (en) 2020-11-05
MX2021007268A (es) 2021-07-15
SG10202012791TA (en) 2021-01-28
US10149842B2 (en) 2018-12-11
US11690836B2 (en) 2023-07-04
TWI902264B (zh) 2025-10-21
MX2021001169A (es) 2023-02-10
MX2016006271A (es) 2017-05-04
SG10201803862UA (en) 2018-06-28
US10596158B2 (en) 2020-03-24
AU2019202144B2 (en) 2020-10-08
AU2020294308A1 (en) 2021-02-18
KR102381295B1 (ko) 2022-03-31
NZ719970A (en) 2022-03-25
CL2016001150A1 (es) 2016-12-09
AR099354A1 (es) 2016-07-20
CR20200220A (es) 2020-11-18
TW201946625A (zh) 2019-12-16
PH12016500866A1 (en) 2016-06-20
WO2015073779A1 (en) 2015-05-21
US20150141467A1 (en) 2015-05-21
US12419877B2 (en) 2025-09-23
BR112016011065B1 (pt) 2022-10-25
TW202126300A (zh) 2021-07-16
ZA201905255B (en) 2020-11-25
KR102495018B1 (ko) 2023-02-06
AU2022259767B2 (en) 2024-08-15
AU2014348523B2 (en) 2019-01-03
RU2021125455A (ru) 2021-10-05
US11065237B2 (en) 2021-07-20
CA2930128A1 (en) 2015-05-21
JP2025011163A (ja) 2025-01-23
BR112016011065A2 (pt) 2017-08-08
BR112016011065A8 (pt) 2020-04-22
NZ759132A (en) 2022-03-25
DOP2016000109A (es) 2016-08-31
TW202335670A (zh) 2023-09-16
AU2022259767A1 (en) 2022-12-01
KR20220042498A (ko) 2022-04-05
TWI665190B (zh) 2019-07-11
EP3068394A4 (en) 2017-04-26
IL245634A0 (en) 2016-06-30
TWI788702B (zh) 2023-01-01
JP2022176961A (ja) 2022-11-30
EP3578546A1 (en) 2019-12-11
JP2020183408A (ja) 2020-11-12
US20190290624A1 (en) 2019-09-26
EP3068394A1 (en) 2016-09-21
US20220040159A1 (en) 2022-02-10
TWI846166B (zh) 2024-06-21
ZA201603189B (en) 2019-11-27
US9701636B2 (en) 2017-07-11
US20180280365A1 (en) 2018-10-04
US20170258773A1 (en) 2017-09-14
RU2016123382A (ru) 2017-12-20
JP2016537365A (ja) 2016-12-01
KR20160083118A (ko) 2016-07-11
TW202435877A (zh) 2024-09-16
MA39033A1 (fr) 2017-11-30
ZA202004764B (en) 2025-10-29
AU2019202144A1 (en) 2019-04-18
PE20160945A1 (es) 2016-09-26
PH12021551124A1 (en) 2024-04-29
IL281648A (en) 2021-05-31
SA516371129B1 (ar) 2019-07-28
AU2020294308B2 (en) 2022-08-11
AR128483A2 (es) 2024-05-15

Similar Documents

Publication Publication Date Title
MX383715B (es) Formas sólidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y usos de las mismas.
SV2018005610A (es) Derivados de oxopiridina sustituidos
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
MX2015003140A (es) Formulaciones de enzalutamida.
MX2015011445A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
GT201400033A (es) Pirimidinas anilladas sustituidas y uso de las mismas
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
GT201200250A (es) Ariltriazolonas ligadas a bisarilo y su uso
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CO6690781A2 (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
UY35350A (es) Pirimidinas condensadas sustituidas con trifluorometilo y su uso
GT201100205A (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
UY35693A (es) Pirazolo[1,5-a]piridin-3-carboxamidas sustituidas y su uso
CO2018001840A2 (es) Composiciones biofarmacéuticas que comprenden anticuerpos anti-il-5
GT201600002A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
CO2019011227A2 (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
DOP2016000076A (es) Tienouracilcarboxamidas cíclicas y usos de las mismas
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
UY35745A (es) Derivados sustituidos de fenilalanina
UY35610A (es) Derivados de prodroga de triazolpiridinas sustituidas
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma